ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$13.58 USD
-0.18 (-1.31%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $13.73 +0.15 (1.10%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADMA 13.58 -0.18(-1.31%)
Will ADMA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ADMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADMA
Adma Biologics (ADMA) Stock Moves -1.31%: What You Should Know
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
ADMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics
Other News for ADMA
Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock 'Hand Over Fist'
Leslie's Issues Preliminary Financial Results, Joins Beyond Meat, Domino's And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights
Adma Biologics price target raised by $2 at Mizuho, here's why
Wall Street Breakfast: The Week Ahead